SRT2104; Placebo
Проводит Sirtris, a GSK Company
Страница компанииA Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00937326/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 30–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 227 чел. во всех странах исследования.
- Плановая дата окончания (09.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 14 · невключение: 10
Критерии включения
- Subjects of any race and gender within the age range of 30 to 70 years.
- All female subjects must be of non-child-bearing potential. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months, or at least 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or women who underwent tubal ligation. Menopausal status will be confirmed by demonstrating levels of follicle stimulating hormone (FSH) 40 - 138 mIU/ml and oestradiol < 20 pg/ml at entry, unless this information is available in the subject's medical record. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH and/or oestradiol levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at the discretion of the principal investigator following consultation with the sponsor and medical monitor
- All male subjects must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 12 weeks following the last dose of study drug.
- Willingness to provide written informed consent to participate in the study
- HbA1c ≥ 7.5 and ≤ 10.5
- Fasting glucose ≥ 160 and ≤ 240 mg/dL
- Body Mass Index (BMI) ≥ 25.0 kg/m\^2 and ≤ 40.0 kg/m\^2
- On stable metformin medication for at least 3 months (≥ 1.0 g/day) prior to Screening
- No prior history of HIV 1 or 2
- Absence of disease markers for hepatitis B \& C virus
- Absence of significant disease or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or physical examination during the screening; normal end organ function
- Have a normal 12-lead ECG or one with abnormality considered to be clinically insignificant
- Have a normal chest X-ray (P. A. View) or one with abnormality considered to be clinically insignificant
- Comprehension of the nature and purpose of the study and compliance with the requirement of the entire protocol
Критерии невключения
- Any major illness in the past three months or any significant ongoing chronic medical illness not related to diabetes
- Renal or liver impairment, defined as serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males, and greater than two times the upper limit of normal for liver enzymes, respectively.
- History of or current gastro-intestinal diseases influencing drug absorption, except for appendectomy
- History, within 3 years, of drug abuse (including Benzodiazepines, opioids, amphetamine, cocaine, and THC)
- History of alcoholism (more than two years), moderate drinkers (more than three drinks per day) or having consumed alcohol within 48 hrs prior to dosing \[one drink is equal to one unit of alcohol (one glass wine, half pint beer, one measure of spirit)\]
- Participation in any clinical trial within the past three months
- History of difficulty in donating blood or accessibility of veins in left or right arm
- Donation of blood (one unit or 350 ml) within three months prior to receiving the first dose of test material
- Use of any prescription drug therapy, with exception of any prescription medication administered at a stable dose for at least 6 weeks prior to Screening, provided the medication is not contraindicated by the metformin label
- Use of any alternate anti-diabetic therapy, except metformin, within three months of enrollment
Источник: ClinicalTrials.gov, NCT00937326 · запись обновлена в реестре 13 июля 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 15
- Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE), AE Related to Study Medication, AE Leading to Discontinuation and Fatal AE of Death — Up to Follow-up (58 days)
- Number of Participants With AE by Intensity of Mild, Moderate and Severe — Up to Follow-up (58 days)
- Mean Change From Baseline in Weight Over Time — Baseline (Day 1) and up to Day 35
- Change From Baseline in Vital Sign Parameter of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Time — Baseline (Day 1, pre-dose) and up to Day 35
- Change From Baseline in Vital Sign Parameter of Heart Rate (HR) Over Time — Baseline (Day 1, pre-dose) and up to Day 35
- Change From Baseline in Vital Sign Parameter of Respiratory Rate (RR) Over Time — Baseline (Day 1, pre-dose) and up to Day 35
- Change From Baseline in Vital Sign Parameter of Temperature Over Time — Baseline (Day 1, pre-dose) and up to Day 35
- Change From Baseline in Electrocardiogram (ECG) Values Over Time — Baseline (Day 1, pre-dose) and up to Day 35
- Change From Baseline in Hematology Parameters of Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet and White Blood Cell (WBC) Count Over Time — Baseline (Day 1) and up to Day 35
- Change From Baseline in Hematology Parameter of Red Blood Cell (RBC) Count Over Time — Baseline (Day 1) and up to Day 35
Цель исследования
The primary purpose of this study is to determine the safety and tolerability of SRT2104 (0.25, 0.5, 1.0, and 2.0 g/day) in type 2 diabetic subjects when administered once daily for 28 consecutive days, and to characterize the pharmacokinetic profile of SRT2104 after a single dose and multiple administrations in type 2 diabetic subjects.
The secondary purpose of this study is to determine the effect of SRT2104 (0.25, 0.5, 1.0, and 2.0 g/day) when administered once daily for 28 consecutive days on fasting blood glucose and insulin and post-prandial blood glucose and insulin in type 2 diabetic subjects.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00937326 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.